NCT03346096View on ClinicalTrials.gov

TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 9, 2018

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Malignant Lymphoma
Interventions
DRUG

Thiotepa

fixed dose 5mg/kg on days -7-6

Trial Locations (1)

57261

Chaim Sheba Medical Center, Ramat Gan

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV

NCT03346096 - TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma | Biotech Hunter | Biotech Hunter